Variable | PathCR | No PathCR | Chi-Sq | p |
---|---|---|---|---|
ER | Â | Â | 0.833 | 0.3613 |
Negative | 7 (35.0%) | 5 (25.0%) | Â | Â |
Positive | 3 (15.0%) | 5 (25.0%) | Â | Â |
PR | Â | Â | 5.000 | 0.0253 |
Negative | 10 (50.0%) | 6 (30.0%) | Â | Â |
Positive | 0 (0.0%) | 4 (20.0%) | Â | Â |
Run-in Treatment | Â | Â | 1.308 | 0.2528 |
Nab-paclitaxel | 7 (30.4%) | 3 (13.1%) | Â | Â |
Trastuzumab | 6 (26.1%) | 7 (30.4%) | Â | Â |